MedTrace Logo

Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis

NCT01420510 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-06-21

No results posted yet for this study

Summary

We hypothesise that the use of Adelmidrol (Saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.

Conditions

  • Vaginitis

Interventions

DRUG

Adelmidrol vaginal gel

Application of a Adelmidrol vaginal gel

DRUG

Placebo vaginal gel

Application of a placebo vaginal gel

Sponsors & Collaborators

  • Università degli Studi dell'Insubria

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420510 on ClinicalTrials.gov